This page shows the latest acromegaly news and features for those working in and with pharma, biotech and healthcare.
Recent estimates put the prevalence of acromegaly at between 115 and 295 cases per million, around double earlier estimates because of a higher-than-thought prevalence of pituitary adenomas. ... Physicians now have a new acromegaly therapy that provides
Somatuline Depot is already available in the US as a treatment for a condition known as acromegaly where patients overproduce a growth hormone. .
This first approval of Signifor in acromegaly marks a much needed advance in the treatment of this rare disease.". ... Signifor LAR has been submitted worldwide for the treatment of acromegaly, with an application filed in the US earlier this year, said
Could add to Signifor’s indications. A phase III trial of Novartis' somatostatin analogue Signifor has suggested it could be effective for the growth hormone disorder acromegaly. ... may offer benefit for acromegaly patients whose disease is not fully
Patient registries such as the Pfizer International Growth Study (KIGS), Pfizer International Metabolic Study (KIMS), Pfizer's ACROSTUDY database for patients with acromegaly, and Shire HGT's Fabry Outcome Survey (FOS)
The licensing deal - valued at up to $595m - is for Octreolin (oral octreotide acetate), a drug candidate which which is currently in phase III testing for acromegaly and also in development ... Our oral octreotide has the potential to improve the
More from news
Approximately 4 fully matching, plus 3 partially matching documents found.
The drug treats the hormonal disorder acromegaly and neuroendocrine tumours (NETs), a rare form of cancer.
Meanwhile, Chiasma remains committed to the development of an oral form of the peptide drug octreotide - a growth hormone inhibitor used to treat acromegaly - despite Roche's decision to hand back
Staying with rare diseases, Cortendo closed a deal with Antisense Therapeutics for ATL 1103 in acromegaly. ... 116. Antisense/ Cortendo. Licence agreement. To develop and market ATL 1103 [P2 ready] in endocrine disorders including acromegaly.
Not all planned alliances however run a smooth course as was the case with the Chiasma/ Roche $600m commercial agreement for Octreolin, the orally acting acromegaly drug.
from Camarus, paying an undisclosed milestone included in their $700 million deal signed two years ago for the indications acromegaly and neuroendocrine tumours.
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
The site opened in 2009 to produce the active ingredients for growth hormone Genotropin (somatropin) and the acromegaly treatment Somavert (pegvisomant).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...